---
title: "Omega Diagnostics Gp (ODX.L) DHSC contract update"
publisher: "Share Talk"
author: "sharetalk"
published: "2021-12-10T12:25:25+00:00"
modified: "2021-12-10T12:25:25+00:00"
date: 2021-12-10
canonical: "https://www.share-talk.com/omega-diagnostics-gp-odx-l-dhsc-contract-update/"
category: "Healthcare"
categories: ["Healthcare", "Pharmaceutical"]
tags: ["Abingdon Health", "Administration", "Antigen Test", "china", "Colin King", "Contract", "COVID-19", "David Grouse", "diagnostic", "diseases", "Drug", "Food", "infectious", "Manufacturing", "Medical", "Mologic Ltd", "ODX", "Omega Diagnostics", "Omega Diagnostics Gp", "Rapid Test", "scientists", "Screen4", "UK Government", "UK-RTC", "University of Oxford"]
image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1"
format: "news"
language: "en-GB"
---

# Omega Diagnostics Gp (ODX.L) DHSC contract update

**Published:** December 10, 2021
**Author:** sharetalk
**Categories:** Healthcare, Pharmaceutical
**Tags:** Abingdon Health, Administration, Antigen Test, china, Colin King, Contract, COVID-19, David Grouse, diagnostic, diseases, Drug, Food, infectious, Manufacturing, Medical, Mologic Ltd, ODX, Omega Diagnostics, Omega Diagnostics Gp, Rapid Test, scientists, Screen4, UK Government, UK-RTC, University of Oxford
**Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1)

---

**Omega (AIM: ODX),** the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, provides an update in relation to the Company’s contract with the Department of Health and Social Care (“DHSC”) to provide manufacturing capacity for COVID-19 lateral flow antigen tests.

As previously disclosed, the DHSC was unable to move into Phase 2 of the contract, which would have seen Omega progress to manufacturing tests using Government-furnished equipment.

Omega has received confirmation from the DHSC that they acknowledge that the contract expired on 1 October 2021 and a request that Omega submit a proposal for the repayment of the pre-production payment of £2.5m (net of VAT).

The Board of Omega, having taken initial legal advice, do not believe that the Company is required to repay the pre-production payment and will respond in writing as requested. The Board will continue to take further legal advice on this matter and hopes to reach a resolution swiftly.

**Colin King, CEO, Omega Diagnostics, said**: “It is clearly disappointing to receive this request for repayment given the efforts we have gone to ensure manufacturing capacity for COVID-19 lateral flow test was available for the DHSC and that we did not progress to Phase 2 of the contract due to the lack of confirmation from the DHSC regarding which test they require us to manufacture.

“Acting in good faith we used these pre-production payments, along with our own funds, to upgrade our manufacturing facilities to be able to integrate the Government-furnished equipment and bringing on the additional staff required to be able to supply the DHSC using our UK-based volume manufacturing services. We therefore are confident that, having sought legal advice, we will not be required to make this repayment.”

**Contacts:**

**Omega Diagnostics Group PLC**

[www.omegadx.com](http://www.omegadx.com)

**Colin King, Chief Executive Officer**

**via Walbrook PR**

**Chris Lea, Chief Financial Officer**

---

**Original URL:** https://www.share-talk.com/omega-diagnostics-gp-odx-l-dhsc-contract-update/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*